Welcome to our dedicated page for ImageneBio SEC filings (Ticker: IMA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ImageneBio's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ImageneBio's regulatory disclosures and financial reporting.
ImageneBio, Inc. has filed a prospectus supplement covering the proposed offer and resale from time to time by selling stockholders of 2,508,337 shares of common stock. The supplement incorporates information from a recent current report that notes Chief Medical Officer Yufang Lu, M.D., Ph.D. has notified the company of her resignation, effective December 31, 2025. The company states that her resignation is not due to any disagreement related to operations, policies or practices. ImageneBio is conducting a search for her replacement, and Dr. Lu is expected to provide transition advisory services after her resignation date. The company’s common stock trades on the Nasdaq Capital Market under the symbol IMA, and last traded at $6.24 per share on December 17, 2025.
Imagenebio, Inc. reported that its Chief Medical Officer, Yufang Lu, M.D., Ph.D., has given notice of her resignation effective December 31, 2025. The company states that Dr. Lu’s decision is not due to any disagreement regarding its operations, policies, or practices, which suggests the change is not driven by internal conflict.
Imagenebio is beginning a search for a new Chief Medical Officer, an important role overseeing its medical and clinical programs. Dr. Lu is expected to provide transition advisory services after her resignation date, helping to maintain continuity in the company’s clinical and medical activities while leadership responsibilities are handed over to her eventual successor.
IMAGENEBIO, INC. (IMA) filed a current report to announce that it has updated its corporate presentation for use in meetings with investors, analysts and other interested parties. The updated presentation, dated November 19, 2025, is being made available on the company’s website and is also included as Exhibit 99.1 to this report.
The company notes that the information in this investor presentation and in this report under Item 7.01 is being furnished rather than filed under securities laws, which means it is not automatically incorporated into other securities filings unless specifically referenced there.
ImageneBio, Inc. (IMA) filed a Form S-8 to register new shares for employee and equity plans. The filing covers 1,118,167 shares of common stock issuable under the ImageneBio, Inc. 2025 Equity Incentive Plan, 111,816 shares under the 2025 Employee Stock Purchase Plan, 589,585 shares under the 2025 Equity Inducement Plan, and 455,938 shares under the Inmagene Biopharmaceuticals 2019 Stock Incentive Plan.
The company notes it completed a merger on July 25, 2025, after which it assumed Legacy Inmagene’s 2019 Stock Incentive Plan and converted outstanding options into options for ImageneBio common stock. The filing also describes standard Delaware-law indemnification for directors and officers, the company’s charter and bylaw protections, and related insurance coverage. This registration facilitates future issuances to employees, directors, and other service providers pursuant to the specified plans.
ImageneBio, Inc. filed a prospectus supplement covering the proposed offer and resale, from time to time, by selling stockholders of 2,508,337 shares of common stock.
The supplement updates the base prospectus by attaching the company’s Quarterly Report on Form 10-Q filed on November 12, 2025. ImageneBio’s common stock trades on the Nasdaq Capital Market under the ticker IMA; the last reported sales price was $8.61 per share on November 11, 2025. The filing reiterates that investing in the securities involves a high degree of risk, directing readers to the Risk Factors in the prospectus.
ImageneBio, Inc. (IMA) filed its Q3 2025 10‑Q and reported a transformative quarter driven by a reverse recapitalization with Ikena Oncology and a concurrent PIPE financing. The company ended September 30, 2025 with cash, cash equivalents and marketable securities of $142.6 million, positioning it to fund operations for at least the next 12 months.
For the quarter, ImageneBio recorded a net loss of $24.8 million, reflecting research and development expense of $15.6 million and general and administrative expense of $11.0 million as it advances its lead program, IMG‑007, a non‑depleting anti‑OX40 monoclonal antibody. For the nine months ended September 30, 2025, net loss totaled $38.4 million.
The July 25, 2025 reverse recapitalization brought in Ikena’s net assets (including $54.6 million of cash and $40.1 million of marketable securities) and the company raised additional capital via a 2,508,339‑share PIPE for approximately $75.0 million gross. A related $22.5 million pre‑merger term loan was forgiven at closing. ImageneBio also completed a Non‑OX40 divestiture, recording a related $7.5 million promissory note receivable and an offsetting CVR liability of $7.5 million. Shares outstanding were 11,181,672 as of November 3, 2025.
ImageneBio, Inc. filed a current report to note that it released its financial results for the quarter ended September 30, 2025. The company announced these quarterly results through a press release dated November 12, 2025, which is included as an exhibit to the report.
The press release is furnished as Exhibit 99.1 and is not deemed filed for liability purposes under the federal securities laws. ImageneBio’s common stock trades on The Nasdaq Capital Market under the symbol IMA.
ImageneBio, Inc. (IMA) reported an insider ownership update. A director filed a Form 3 initial statement of beneficial ownership effective 11/01/2025, indicating no securities are beneficially owned. The filing was made by one reporting person, and includes an Exhibit 24 Power of Attorney authorizing the attorney-in-fact to sign on the reporting person’s behalf.
This is a routine disclosure establishing the insider’s baseline ownership at the time they became subject to reporting.
ImageneBio filed a Rule 424(b)(3) prospectus supplement to its Form S-1, relating to the proposed offer and resale from time to time by selling stockholders of 2,508,337 shares of common stock. The supplement updates the prospectus with information from a Current Report on Form 8-K. The company’s common stock trades on Nasdaq as “IMA,” and the last reported sales price was $8.24 per share on November 4, 2025.
The attached 8-K reports the Board increased its authorized size from six to seven directors and appointed Joseph P. Slattery to the Board effective November 1, 2025, and as Chair of the Audit Committee effective November 18, 2025. The company entered into its standard indemnification agreement with Mr. Slattery.
ImageneBio, Inc. expanded its Board of Directors from six to seven and appointed Joseph P. Slattery as a director effective November 1, 2025. He will serve as Chair of the Audit Committee effective November 18, 2025.
The company entered into its standard indemnification agreement with Mr. Slattery in the form previously filed as Exhibit 10.10 to its Form S-1.